Eris Lifesciences Limited has informed the Exchange about Credit Rating
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
India Ratings and Research has affirmed Eris Lifesciences' Long-term Issuer Rating and bank facility ratings at 'IND AA' with a Stable outlook. The rating affirmation reflects the company's sustained healthy operating performance with EBITDA of INR 8.5 billion in 9MFY26 and EBITDA margins of over 35%. The company improved its net leverage to 2.2x in FY25 from 3.9x in FY24, driven by strong cash flow conversion and debt reduction. Eris has expanded its manufacturing base to six facilities and grown its international exports to 11% of revenue. The company has completed multiple strategic acquisitions including full ownership of Swiss Parenterals and Biocon's Indian formulation business.
The stable rating affirmation with 'IND AA' grade indicates strong creditworthiness and low default risk. Shareholders can view this as a positive signal showing the company's ability to manage its debt obligations and integrate acquisitions successfully. The rating suggests the stock could be considered by investors seeking exposure to high-quality pharmaceutical companies with stable credit profiles.